Physiological promoters reduce the genotoxic risk of integrating gene vectors

Molecular Therapy

Volumn 16, Issue 4, 2008, Pages 718-725

  Zychlinski, Daniela ^a   Schambach, Axel ^a   Modlich, Ute ^a   Maetzig, Tobias ^a   Meyer, Johann ^a   Grassman, Elke ^b   Mishra, Anjali ^b   Baum, Christopher ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELONGATION FACTOR 1ALPHA; ONCOPROTEIN; PHOSPHOGLYCERATE KINASE; PROTEIN EVI1; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ASSAY; ENHANCER REGION; GENE INSERTION; GENE INTERACTION; GENE VECTOR; GENETIC TRANSFORMATION; GENOTOXICITY; HEMATOPOIETIC CELL; MOUSE; NONHUMAN; PROMOTER REGION; RISK REDUCTION; SELF INACTIVATING VECTOR; VIRAL GENE DELIVERY SYSTEM;

EID: 41149133413     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.5     Document Type: Article

References (34)

1. Li, Z, Dullmann, J, Schiedlmeier, B, Schmidt, M, von Kalle, C, Meyer, J et al. (2002). Murine leukemia induced by retroviral gene marking. Science 296: 497.
2. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
3. Nienhuis, AW, Dunbar, CE and Sorrentino, BP (2006). Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 13: 1031-1049.
4. Modlich, U, Kustikova, O, Schmidt, M, Rudolph, C, Meyer, J, Li, Z et al. (2005). Leukemias following retroviral transfer of multidrug resistance 1 are driven by combinatorial insertional mutagenesis. Blood 105: 4235-4246.
5. Kustikova, OS, Fehse, B, Modlich, U, Yang, M, Düllmann, J, Kamino, K et al. (2005). Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308: 1171-1174.
6. Modlich, U, Bohne, J, Schmidt, M, von Kalle, C, Knoss, S, Schambach, A et al. (2006). Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108: 2545-2553.
7. Du, Y, Jenkins, NA and Copeland, NG (2005). Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood 106: 3932-3939.
8. Du, Y, Spence, SE, Jenkins, NA and Copeland, NG (2005). Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. Blood 106: 2498-2505.
9. Seggewiss, R, Pittaluga, S, Adler, RL, Guenaga, FJ, Ferguson, C, Pilz, J et al. (2006). Acute myeloid leukemia associated with retroviral gene transfer to hematopoietic progenitor cells of a rhesus macaque. Blood 107: 3865-3867.
10. Ott, MG, Schmidt, M, Schwarzwaelder, K, Stein, S, Siler, U, Koehl, U et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
11. Shou, Y, Ma, Z, Lu, T and Sorrentino, BP (2006). Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci USA 103: 11730-11735.
12. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Ponzoni, M, Bartholomae, C et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24: 687-696.
13. Kim, DW, Uetsuki, T, Kaziro, Y, Yamaguchi, N and Sugano, S (1990). Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. Gene 91: 217-223.
14. Salmon, P, Kindler, V, Ducrey, O, Chapuis, B, Zubler, RH and Trono, D (2000). High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood 96: 3392-3398.
15. Schambach, A, Bohne, J, Chandra, S, Will, E, Margison, GP, Williams, DA et al. (2006). Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther 13: 391-400.
16. Wahlers, A, Zipfel, PF, Schwieger, M, Ostertag, W and Baum, C (2002). In vivo analysis of retroviral enhancer mutations in hematopoletic cells: SP1/EGR1 and ETS/GATA motifs contribute to long terminal repeat specificity. J Virol 76: 303-312.
17. Wakabayashi-Ito, N and Nagata, S (1994). Characterization of the regulatory elements in the promoter of the human elongation factor-1α gene. J Biol Chem 269: 29831-29837.
18. Baum, C, Itoh, K, Meyer, J, Laker, C, Ito, Y and Ostertag, W (1997). The potent enhancer activity of SFFVp in hematopoietic cells is governed by a binding site for Sp1 in the upstream control region and by a unique enhancer core creating an exclusive target for PEBP/CBF. J Virol 71: 6323-6331.
19. Wahlers, A, Kustikova, O, Zipfel, PF, Itoh, K, Koester, M, Heberlein, C et al. (2002). Upstream conserved sequences of mouse leukemia viruses are important for high transgene expression in lymphoid and hematopoletic cells. Mol Ther 6: 313-320.
20. Bell, AC, West, AG and Felsenfeld, G (1999). The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. Cell 98: 387-396.
21. Okey, AB, Harper, PA, Grant, DM and Hill, RP (2005). Chemical and radiation carcinogenesis. In: Tannock, IF, Hill, RP, Bristow, RG and Harrington, L (eds). The Basic Science of Oncology. McGraw-Hill: New York. pp. 25-48.
22. Cattoglio, C, Facchini, G, Sartori, D, Antonelli, A, Miccio, A. Cassani, B et al. (2007). Hot spots of retroviral integration in human CD34+ hematopoletic cells. Blood 110: 1770-1778.
23. Kustikova, O, Geiger, H, Li, Z, Brugman, MH, Chambers, SM, Shaw, CA et al. (2007). Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" patnways. Blood 109: 1897-1907.
24. Robert-Richard, E, Richard, E, Malik, P, Ged, C, de Verneuil, H and Moreau-Gaudry, F (2007). Murine retroviral but not human cellular promoters induce in vivo erythroid-specific deregulation that can be partially prevented by insulators. Mol Ther 15: 173-182.
25. Weber, EL and Cannon, PM (2007). Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential. Hum Gene Ther 18: 849-860.
26. Evans-Galea, MV, Wielgosz, MM, Hanawa, H, Srivastava, DK and Nienhuls, AW (2007). Suppression of clonall dominance in cultured human lymphoid cells by addition of the chs4 insulator to a lentiviral vector. Mol Ther 15: 801-809.
27. Aker, M, Tubb, J, Groth, AC, Bukovsky, AA, Bell, AC, Felsenfeld, G et al. (2007). Extended core sequences from the cHS4 insulator am necessary for protecting retroviral vectors from silencing position effects. Hum Gene Ther 18: 333-343.
28. Emery, DW, Yannaki, E, Tubb, I and Stamatoyannopoulos, G (2000). A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc Natl Acad Sci USA 97: 9150-9155.
29. Baens, M, Noels, H, Broeckx, V, Hagens, S, Fevery, S, Billiau, AD et al. (2006). The dark side of EGFP: Defective polyubiquitination. PLoS ONE 1: E54.
30. Schambach, A, Bohne, J, Baum, C, Hermann, FG, Egerer, L, von Laer, D et al. (2006). Woodchuck hepatitis vinis post-transcriptioinal regulatory element deleted from X protein and promoter sequences énhances retroviril vector titer and expression. Gene Ther 13: 641-645.
31. Morita, S, Kojima, T and Kitamura, T (2000). Plat-E: An efficient and stable system for transient packaging of retroviruses. Gene Ther 7: 1063-1070.
32. Li, Z,~Schwieger, M, Lange, C, Kraunus, J, Sun, H, van den Akker, E et al. (2003). Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose. Exp Hematol 31: 1206-1214.
33. Schambach, A, Mueller, D, Galla, M, Verstegen, MM, Wagemaker, G, Loew, R et al. (2006). Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Ther 13: 1524-1533.
34. Schambach, A, Galla, M, Maetzig, T, Loew, R and Baum, C (2007). Improving transcriptional termination of self-inactivating gamma-retroviral arid lentiviral vectors. Mol Ther 15: 1167-1173.